Respuesta de anticuerpos COVID-19 inducida por la vacuna ARNm BNT162b2 en trabajadores de atención médica de primera línea

The emergence of SARS-CoV-2, the virus causing COVID-19, has resulted in a pandemic that has disrupted all sectors of society. Less than a year after the sequencing of the virus’s genome, emergency use authorization for the BNT162b2 vaccine was requested. The aim of this study was to evaluate the response to the BNT162b2-mRNA COVID-19 vaccine in frontline workers from two hospitals in Colombia. Nasopharyngeal swabs were collected for the molecular detection of SARS-CoV-2 using real-time PCR, and blood samples were taken to assess seroconversion using qualitative and quantitative IgA, IgG, and IgM test kits. The study was conducted at a high-complexity healthcare institution in Bucaramanga, Colombia. 245 people were included in the first round and 129 in the second. SARS-CoV-2 molecular tests were conducted by RT-qPCR, and peripheral blood samples were collected to measure IgG, IgM, and IgA. The main outcome was to establish natural infection and the antibody response induced by the vaccine. The entire population was tested at two fixed times with RT-PCR tests and antibody level measurements approximately 4 and 8 months after receiving the second vaccine dose. 62 (25.3%) and 35 (14.3%) participants had a history of positive PCR in the first and second rounds, respectively. All positive cases showed elevated levels of all immunoglobulins, especially IgG. The average concentrations of IgA, IgM, and IgG at 90 days were 1149.5 U/mL (95% CI 828.2-1470.9); 320.3 U/mL (95% CI 218.4-422.3); and 9277.3 U/mL (95% CI 8989.2-9565.3). Frontline healthcare workers showed an adequate response to the BNT162b2 mRNA vaccine. La aparición del SARS-CoV-2, causante de la COVID-19, resultó en una pandemia que afectó a todos los sectores de la sociedad. Menos de un año después de la secuenciación del genoma del virus, se solicitó el uso de emergencia para la vacuna BNT162b2. El objetivo de este trabajo fue evaluar la respuesta a la vacuna BNT162b2-mRNA COVID-19 en trabajadores de primera línea de dos hospitales en Colombia. Se tomaron muestras nasofaríngeas para la detección del SARS-CoV-2 mediante PCR en tiempo real y muestras de sangre para evaluar la seroconversión con kits de prueba IgA, IgG e IgM. El estudio se realizó en una institución de salud de alta complejidad en Bucaramanga, Colombia. Se incluyeron 245 personas en la primera ronda y 129 en la segunda. Las pruebas moleculares de SARSCoV-2 se realizaron por RT-qPCR y se obtuvieron muestras de sangre periférica para medi